Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.
The major obstacle to glioblastoma pharmacological therapy is the overcoming of the blood-brain barrier (BBB). In literature, several strategies have been proposed to overcome the BBB: in this experimental work, solid lipid nanoparticles (SLN), prepared according to fatty acid coacervation technique, are proposed as the vehicle for doxorubicin (Dox), to enhance its permeation through an artificial model of BBB. The in vitro cytotoxicity of Dox-loaded SLN has been measured on three different commercial and patient-derived glioma cell lines. Dox was entrapped within SLN thanks to hydrophobic ion pairing with negatively charged surfactants, used as counterions. Results indicate that Dox entrapped in SLN maintains its cytotoxic activity toward glioma cell lines; moreover, its permeation through hCMEC/D3 cell monolayer, assumed as a model of the BBB, was increased when the drug was entrapped in SLN. In conclusion, SLN proved to be a promising vehicle for the delivery of Dox to the brain in glioblastoma treatment.
Università degli Studi di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italy. Electronic address: luigi.battaglia@unito.it.
Luigi
L
Battaglia
Università degli Studi di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italy.
Marina
M
Gallarate
Università degli Studi di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italy.
Elena
E
Peira
Università degli Studi di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italy.
Daniela
D
Chirio
Università degli Studi di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italy.
Elisabetta
E
Muntoni
Università degli Studi di Torino, Dipartimento di Scienze Veterinarie, Grugliasco, Italy.
Elena
E
Biasibetti
Università degli Studi di Torino, Dipartimento di Scienze Veterinarie, Grugliasco, Italy.
Maria Teresa
MT
Capucchio
Università degli Studi di Torino, Dipartimento di Scienze Veterinarie, Grugliasco, Italy.
Alberto
A
Valazza
Università degli Studi di Torino, Dipartimento di Neuroscienze, Torino, Italy.
Pier Paolo
PP
Panciani
Università degli Studi di Torino, Dipartimento di Neuroscienze, Torino, Italy.
Michele
M
Lanotte
Centro di NeuroBioOncologia, Policlinico di Monza, Vercelli, Italy.
Davide
D
Schiffer
Centro di NeuroBioOncologia, Policlinico di Monza, Vercelli, Italy.
Laura
L
Annovazzi
Centro di NeuroBioOncologia, Policlinico di Monza, Vercelli, Italy.
Valentina
V
Caldera
Centro di NeuroBioOncologia, Policlinico di Monza, Vercelli, Italy.
Marta
M
Mellai
Università degli Studi di Torino, Dipartimento di Oncologia, Orbassano, Italy.
Chiara
C
Riganti
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology*; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004337:Drug Carriers / Q000737:chemistry*; D065546:Drug Liberation; D005227:Fatty Acids / Q000737:chemistry*; D005909:Glioblastoma / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D010539:Permeability; D061251:Primary Cell Culture; D012995:Solubility; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D005227:Fatty Acids; D004317:Doxorubicin
CNS; SLN; blood-brain barrier; coacervation; doxorubicin; glioblastoma; ion pairing; nanoparticles